Working…
Help guide our efforts to modernize ClinicalTrials.gov.
Send us your comments by March 14, 2020.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Quantitative Renal Uptake Using TC99m DMSA in Hypertensive &/or Diabetic Patients.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03123237
Recruitment Status : Unknown
Verified April 2017 by Hebat Allah Ahmed Askar, Assiut University.
Recruitment status was:  Recruiting
First Posted : April 21, 2017
Last Update Posted : April 21, 2017
Sponsor:
Information provided by (Responsible Party):
Hebat Allah Ahmed Askar, Assiut University

Brief Summary:
the investigators explore the possible role of DMSA to detect renal affection in diabetic &/or hypertensive patients by detecting difference in counts using Tc 99m DMSA in control & diabetic &/or hypertensive patients.

Condition or disease Intervention/treatment Phase
Diabetes Mellitus Hypertension Diagnostic Test: DMSA scan Phase 4

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 45 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Quantitative Renal Uptake Using TC99m DMSA in Hypertensive &/or Diabetic Patients.
Actual Study Start Date : July 2016
Estimated Primary Completion Date : October 2017
Estimated Study Completion Date : December 2017

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Placebo Comparator: Control

control will be subjected to:

• Quantitative Tc99m DMSA renal scan using SPECT technique.

Diagnostic Test: DMSA scan
We explore the possible role of DMSA to detect renal affection in diabetic &/or hypertensive patients by detecting difference in counts using Tc 99m DMSA in control & diabetic &/or hypertensive patients.

Active Comparator: Diabetic

diabetic cases will be subjected to:

• Quantitative Tc99m DMSA renal scan using SPECT technique.

Diagnostic Test: DMSA scan
We explore the possible role of DMSA to detect renal affection in diabetic &/or hypertensive patients by detecting difference in counts using Tc 99m DMSA in control & diabetic &/or hypertensive patients.

Active Comparator: Hypertensive

hypertesive cases will be subjected to:

• Quantitative Tc99m DMSA renal scan using SPECT technique.

Diagnostic Test: DMSA scan
We explore the possible role of DMSA to detect renal affection in diabetic &/or hypertensive patients by detecting difference in counts using Tc 99m DMSA in control & diabetic &/or hypertensive patients.

Active Comparator: Diabetic & Hypertensive

Diabetic & Hypertensive cases will be subjected to:

• Quantitative Tc99m DMSA renal scan using SPECT technique.

Diagnostic Test: DMSA scan
We explore the possible role of DMSA to detect renal affection in diabetic &/or hypertensive patients by detecting difference in counts using Tc 99m DMSA in control & diabetic &/or hypertensive patients.




Primary Outcome Measures :
  1. Renal Counts [ Time Frame: 2-4 hours ]
    Quantitative Tc99m DMSA renal scan using SPECT technique will be used to measure renal function.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • • Patients with diabetes (type2), weather controlled or not.

    • Patients with essential hypertension.
    • Patients with diabetes & hypertension.
    • Within normal renal function (urea & creatinine).
    • Control cases may be normal individuals (apparently healthy) like donors for renal transplant.

Exclusion Criteria:

  • • Patients with abnormal renal function.

    • Patients with diseases known to affect kidney function rather diabetes & hypertension e.g. SLE, heart failure or liver cell failure.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03123237


Contacts
Layout table for location contacts
Contact: Heba Askar, MsC +201003040898 hebaaskar@aun.edu.eg

Locations
Layout table for location information
Egypt
Assiut university Recruiting
Assiut, Egypt
Sponsors and Collaborators
Assiut University

Layout table for additonal information
Responsible Party: Hebat Allah Ahmed Askar, Principle investigator, Assiut University
ClinicalTrials.gov Identifier: NCT03123237    
Other Study ID Numbers: DMSA
First Posted: April 21, 2017    Key Record Dates
Last Update Posted: April 21, 2017
Last Verified: April 2017

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Hypertension
Vascular Diseases
Cardiovascular Diseases
Succimer
Antidotes
Protective Agents
Physiological Effects of Drugs
Chelating Agents
Sequestering Agents
Molecular Mechanisms of Pharmacological Action